25 results
Thumbnail

D1.116 - Severe Airflow Limitation Unmasked by NSAID Hypersensitivity: A Case of Undiagnosed Persistent Asthma with Nasal Polyposis

Thumbnail

D1.117 - Combing dual biologics therapy for severe asthma : a series of ten cases

Thumbnail

D1.118 - The Use of Long-Acting Muscarinic Antagonist in the Treatment of Asthma: A Latin-American 2 Specialized Asthma Center Experience

Thumbnail

D1.119 - Anti-Inflammatory Effects of miRNA-Mediated Extracellular Vesicles Derived from Mesenchymal Stem Cells in a Murine Asthma Model

Thumbnail

D1.122 - Hydrogen peroxide in exhaled breath condensate as a marker for monitoring biologic treatment response in severe asthmatic patients

Thumbnail

D1.123 - Inhibition of the Interleukin Cytokines using novel Peptide Inhibitors for Allergy and Asthma Treatment

Thumbnail

D1.124 - Predictive Factors of Clinical Remission in Severe Eosinophilic Asthma Treated with Benralizumab

Thumbnail

D1.125 - Biological therapy in severe asthma: 20 years of experience at the Hospital Universitario de Burgos

Thumbnail

D1.126 - Deciphering Genetic Causal Relationships and Molecular Mechanisms Linking Multiple Allergic Diseases and Schizophrenia

Thumbnail

D1.127 - Distinct roles of Natural killer T Cells and Innate Lymphoid Cells in Type I and II airway Inflammation Induced by Viral Infection

Thumbnail

D1.128 - Dupilumab in a Child with Severe Allergic Asthma, Atopic Dermatitis, Vernal Keratoconjunctivitis, and Partial IgA Deficiency

Thumbnail

D1.129 - Bispecific Antibody Targeting IL-33 and TSLP for Treating Asthma and COPD

Thumbnail

D1.130 - Associations between Serum Clara Cell Protein 16 (CC16) and Asthma Severity in Children

Thumbnail

D1.131 - TRough levels In plasma of dUpilumab and Mepolizumab in Patients with severe astHma (TRIUMPH)

Thumbnail

D1.133 - Nature Prescription: Another Alternative Therapy for Patients with Chronic Respiratory Disease – Pilot Study

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates